Rupal Bhatt News Today

Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide.

Promising Triple Therapy Approach Identified for Renal Cell Carcinoma January 21, 2021 Source: Kateryna Kon/Science Photo Library/Getty Images Researchers in the U.S. and Ireland have discovered that combining VEGFR inhibitor drugs with a peptide, angiotensin-(1,7), which is generated by the ACE2 enzyme, can overcome treatment resistance and improve survival in mice with renal cell carcinoma (RCC), a common kidney cancer. The team’s analysis of human RCC ACE2 expression data suggested that A...

Researchers Uncover Promising Combination for Renal Cancer by Angela Mohan on  January 21, 2021 at 12:29 PM Loss of ACE2 mediates resistance to classical treatments to renal cell carcinoma (RCC) , and treatment with a drug that could downstream ACE2, can improve tumor responses in RCC and prolong survival. Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cance...

 E-Mail Boston, Mass. -- Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the effi...